黑色素瘤治療研究進(jìn)展
發(fā)布時(shí)間：2019-06-10 18:41
【摘要】：黑色素瘤是一種曾經(jīng)讓醫(yī)生束手無策的惡性腫瘤,既往治療手段有限,放療、化療及傳統(tǒng)免疫治療療效不佳,患者預(yù)后極差。2011年以來,小分子靶向藥物(包括BRAF抑制劑Vemurafenib、Dabrafenib,MEK抑制劑Trametinib等藥物)相繼面世,預(yù)示著黑色素瘤內(nèi)科治療進(jìn)入一個(gè)新的研究階段。而免疫靶向治療(如抗CTLA-4抗體,抗PD-1、PD-L1抗體)在多項(xiàng)臨床試驗(yàn)中的成功,更是締造了腫瘤治療的新理念。黑色素瘤治療逐漸擺脫傳統(tǒng)抗腫瘤治療的模式,進(jìn)入一個(gè)嶄新的歷史階段,在可預(yù)見的將來,新治療靶點(diǎn)的研發(fā)、多種小分子靶向藥物、多種免疫靶向藥物的聯(lián)合治療,以及小分子靶向藥物和免疫靶向藥物的聯(lián)合治療等模式將會(huì)是黑色素瘤治療的主流。本文主要從小分子靶向藥物治療、免疫靶向治療、化療3個(gè)方面綜述黑色素瘤治療的研究進(jìn)展。
[Abstract]:Melanoma is a malignant tumor that once left doctors helpless. Previous treatments are limited, radiotherapy, chemotherapy and traditional immunotherapy are not effective, and the prognosis of patients is very poor. Since 2011, small molecule targeting drugs (including BRAF inhibitor Vemurafenib,) Dabrafenib,MEK inhibitor Trametinib and other drugs have been introduced one after another, indicating that the medical treatment of melanoma has entered a new stage of research. The success of immunotargeted therapy (such as anti-CTLA-4 antibody, anti-PD-1,PD-L1 antibody) in many clinical trials has created a new concept of tumor treatment. Melanoma treatment gradually got rid of the traditional anti-tumor treatment model and entered a new historical stage. In the foreseeable future, the research and development of new treatment targets, a variety of small molecule targeted drugs, a variety of immunotargeted drugs combined treatment. And the combination of small molecule targeted drugs and immunotargeted drugs will be the mainstream of melanoma treatment. In this paper, the research progress of melanoma treatment was reviewed in three aspects: small molecular targeted drug therapy, immunotargeted therapy and chemotherapy.
【作者單位】： 北京大學(xué)腫瘤醫(yī)院;北京市腫瘤防治研究所腎癌黑色素瘤內(nèi)科;惡性腫瘤發(fā)病機(jī)制及轉(zhuǎn)移研究教育部重點(diǎn)實(shí)驗(yàn)室;
【分類號(hào)】：R739.5
[Abstract]:Melanoma is a malignant tumor that once left doctors helpless. Previous treatments are limited, radiotherapy, chemotherapy and traditional immunotherapy are not effective, and the prognosis of patients is very poor. Since 2011, small molecule targeting drugs (including BRAF inhibitor Vemurafenib,) Dabrafenib,MEK inhibitor Trametinib and other drugs have been introduced one after another, indicating that the medical treatment of melanoma has entered a new stage of research. The success of immunotargeted therapy (such as anti-CTLA-4 antibody, anti-PD-1,PD-L1 antibody) in many clinical trials has created a new concept of tumor treatment. Melanoma treatment gradually got rid of the traditional anti-tumor treatment model and entered a new historical stage. In the foreseeable future, the research and development of new treatment targets, a variety of small molecule targeted drugs, a variety of immunotargeted drugs combined treatment. And the combination of small molecule targeted drugs and immunotargeted drugs will be the mainstream of melanoma treatment. In this paper, the research progress of melanoma treatment was reviewed in three aspects: small molecular targeted drug therapy, immunotargeted therapy and chemotherapy.
【作者單位】： 北京大學(xué)腫瘤醫(yī)院;北京市腫瘤防治研究所腎癌黑色素瘤內(nèi)科;惡性腫瘤發(fā)病機(jī)制及轉(zhuǎn)移研究教育部重點(diǎn)實(shí)驗(yàn)室;
【分類號(hào)】：R739.5
【共引文獻(xiàn)】
相關(guān)期刊論文 前9條
1 Meng-Ze Hao;Wen-Ya Zhou;Xiao-Ling Du;Ke-Xin Chen;Guo-Wen Wang;Yun Yang;Ji-Long Yang;;Novel anti-melanoma treatment:focus on immunotherapy[J];Chinese Journal of Cancer;2014年09期
2 敖俊紅;楊蓉婭;;轉(zhuǎn)移性黑素瘤的治療選擇[J];實(shí)用皮膚病學(xué)雜志;2013年04期
3 鄭永卿;劉文超;;晚期黑色素瘤的個(gè)體化靶向治療研究進(jìn)展[J];實(shí)用腫瘤雜志;2014年01期
4 田慧;耿傲蕾;鄧驥;;聯(lián)合運(yùn)用化療藥物、疫苗和單克隆抗體進(jìn)行抗癌治療[J];中國(guó)藥房;2010年38期
5 張艷麗;祝順琴;劉亞玲;崔紅娟;;惡性黑色素瘤內(nèi)科治療研究進(jìn)展[J];腫瘤防治研究;2014年01期
6 袁溪;杜蓉;魏靜;魏e，
本文編號(hào)：2496652
本文鏈接：http://sikaile.net/yixuelunwen/pifb/2496652.html
最近更新
教材專著
